News | January 22, 2014

Elixir Completes First Commercial Implant Of Fully Bioresorbable Stent

Patient in Germany receives fully bioresorbable scaffold designed to degrade in one year

Elixir Medical DESolve Bioresorbable Coronary Scaffold System Stents
January 22, 2014 — The first commercial implant of Elixir Medical’s CE Mark-approved DESolve Novolimus Eluting Coronary Scaffold was performed in Germany by Prof. Dr. med. Holger Nef, head of the Cardiac Catheterization Laboratory, University Hospital Giessen, Giessen, Germany.
 
Elixir’s fully bioresorbable DESolve scaffold for coronary artery disease restores blood flow to the heart like metallic stents and then dissolves, resulting in a functional artery free of a permanent implant. Developed from a poly-L Lactide (PLLA)-based polymer, DESolve attempts to provide strength and support to arteries while delivering the anti-proliferative drug, Novolimus. It intends to maintain radial strength and vessel support during healing while degrading in one year, increase lumen area within six months, self-appose to the vessel wall up to the nominal deployed diameter and provide a wide margin of expansion.
 
“The fully bioresorbable DESolve System is easy to deliver. The acute performance of the scaffold demonstrated excellent stent apposition to the vessel wall and low recoil, and the patient is doing well,” Nef said.
 
The DESolve Nx pivotal trial enrolled 126 patients at 13 centers in Europe, Brazil and New Zealand. 1-year safety and efficacy results for the DESolve Novolimus Eluting Coronary Scaffold System were announced at the October 2013 Transcatheter Therapeutics scientific conference in San Francisco. At that time, the DESolve Nx trial had demonstrated a low Major Adverse Cardiac Events (MACE) rate of 5.69 percent with no definite scaffold thrombosis. 
 
The fully bioresorbable DESolve Novolimus Eluting Scaffold System is currently available in diameters of 3.0, 3.25 and 3.5 mm and lengths of 14, 18 and 28 mm. Additional sizes will be available in 2014.
 
For more information: www.elixirmedical.com

Related Content

Bioresorbable stents (BRS) in development presented by Gregg Stone, M.D., during TCT 2017. Several of the players listed on the slider put their BRS development programs on hold after the negative data from the ABSORB III Trial, but a handful of smaller companies are still pushing the technology forward. #TCT #TCT2018

Bioresorbable stents (BRS) in development, presented by Gregg Stone, M.D., during TCT 2017. Several of the players listed on the slider put their BRS development programs on hold after the negative data from the ABSORB III Trial, but a handful of smaller companies are still pushing the technology forward.

Feature | Stents Bioresorbable | October 12, 2018 | Dave Fornell, Editor
Bioresorbable stent (BRS) technology is not dead, but the unbridled enthusiasm seen two years ago for the technology
A comparison of target lesion failure (TLF) of the Reva bioresorbable stent to the Absorb and top performing metallic DES. #TCT #TCT2018 #TCT18 #BRS #bioresorbablestents #bioresorbablescaffolds

A comparison of target lesion failure (TLF) of the Reva bioresorbable stent to the Absorb and top performing metallic DES. 

News | Stents Bioresorbable | October 12, 2018
October 12, 2018 – Reva Medical presented four key data sets demonstrating the capabilities of the company’s Fantom
Magnitude Bioresorbable Scaffold Shows Low MACE, Restenosis Rates at Nine Months
News | Stents Bioresorbable | October 01, 2018
New results from the RENASCENT studies presented at the Transcatheter Cardiovascular Therapeutics (TCT) conference...
Videos | Stents Bioresorbable | August 06, 2018
Patrick Serruys, M.D., Ph.D., Imperial College London, explains where development of bioresorbable scaffolds stands i
Amaranth's Fortitute bioresorbable stent scaffold. The company is developing smaller strut BRS.  Data presented at EuroPCR 2018
Feature | Stents Bioresorbable | June 19, 2018
June 19, 2018 – Amaranth Medical offered new details about its 85-micron Defiance bioresorbable scaffold (BRS) recent
Videos | Stents Bioresorbable | November 07, 2017
A discussion with Ajay Kirtane, M.D., SM, director of the cardiac catheterization laboratories at New York-Presbyteri
Thirty-Day ABSORB IV Results Demonstrate Improvements Still Needed in Bioresorbable Stents
News | Stents Bioresorbable | October 31, 2017
Thirty-day results from ABSORB IV, the largest randomized everolimus-eluting bioresorbable vascular scaffold (BVS)...
Amaranth Medical to Share Bioresorbable Scaffold Data at TCT
News | Stents Bioresorbable | October 25, 2017
Amaranth Medical will provide an update at the annual Transcatheter Cardiovascular Therapeutics (TCT) meeting, Oct. 29-...
Abbott will end sales of the Absorb bioresorbable stent scaffold, pulling it off the market September 14, 2017.
Feature | Stents Bioresorbable | September 08, 2017 | Dave Fornell
September 8, 2017 — Abbott Vascular has announced it will end commercial sales of its Absorb bioresorbable vascular s
Overlay Init